Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)’s share price gapped up before the market opened on Monday . The stock had previously closed at $1.38, but opened at $1.41. Aralez Pharmaceuticals shares last traded at $1.48, with a volume of 2244400 shares traded.
The company has a quick ratio of 0.92, a current ratio of 1.00 and a debt-to-equity ratio of 4.64.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. The firm had revenue of $24.30 million during the quarter, compared to the consensus estimate of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The company’s revenue was up 78.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. equities analysts anticipate that Aralez Pharmaceuticals Inc. will post -1.54 EPS for the current year.
Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its stake in shares of Aralez Pharmaceuticals by 0.3% during the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock worth $260,000 after purchasing an additional 354 shares in the last quarter. Isthmus Partners LLC grew its stake in shares of Aralez Pharmaceuticals by 0.8% during the second quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock worth $208,000 after purchasing an additional 1,285 shares in the last quarter. Ballentine Partners LLC grew its stake in shares of Aralez Pharmaceuticals by 166.7% during the third quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock worth $183,000 after purchasing an additional 50,000 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Aralez Pharmaceuticals by 71.3% in the third quarter. Wells Fargo & Company MN now owns 273,130 shares of the company’s stock valued at $625,000 after acquiring an additional 113,720 shares in the last quarter. Finally, Brown Advisory Securities LLC acquired a new position in Aralez Pharmaceuticals in the third quarter valued at $394,000. Hedge funds and other institutional investors own 19.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/18/aralez-pharmaceuticals-arlz-shares-gap-up-to-1-41.html.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.